Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/4317
Title: The Use of Exhaled Nitric Oxide to Guide Asthma Management: A Randomised Controlled Trial.
Authors: Shaw, D. E.
Berry, Mike A.
Thomas, M.
Green, R. H.
Brightling, Christopher E.
Wardlaw, Andrew J.
Pavord, Ian D.
First Published: 11-May-2007
Publisher: American Thoracic Society.
Citation: American Journal of Respiratory and Critical Care Medicine, 2007, 176, pp. 231-237.
Abstract: Rationale: Current asthma guidelines recommend adjusting antiinflammatory treatment on the basis of the results of lung function tests and symptom assessment, neither of which are closely associated with airway inflammation. Objectives: We tested the hypothesis that titrating corticosteroid dose using the concentration of exhaled nitric oxide in exhaled breath (FENO) results in fewer asthma exacerbations and more efficient use of corticosteroids, when compared with traditional management. Methods: One hundred eighteen participants with a primary care diagnosis of asthma were randomized to a single-blind trial of corticosteroid therapy based on either FENO measurements (n = 58) or British Thoracic Society guidelines (n = 60). Participants were assessed monthly for 4 months and then every 2 months for a further 8 months. The primary outcome was the number of severe asthma exacerbations. Analyses were by intention to treat. Measurements and Main Results: The estimated mean (SD) exacerbation frequency was 0.33 per patient per year (0.69) in the FENO group and 0.42 (0.79) in the control group (mean difference, –21%; 95% confidence interval [CI], –57 to 43%; p = 0.43). Overall the FENO group used 11% more inhaled corticosteroid (95% CI, –17 to 42%; p = 0.40), although the final daily dose of inhaled corticosteroid was lower in the FENO group (557 vs. 895 µg; mean difference, 338 µg; 95% CI, –640 to –37; p = 0.028). Conclusions: An asthma treatment strategy based on the measurement of exhaled nitric oxide did not result in a large reduction in asthma exacerbations or in the total amount of inhaled corticosteroid therapy used over 12 mo, when compared with current asthma guidelines.
DOI Link: 10.1164/rccm.200610-1427OC
ISSN: 1073-449X
Links: http://www.atsjournals.org/doi/abs/10.1164/rccm.200610-1427OC
http://hdl.handle.net/2381/4317
Type: Article
Rights: This is the author’s final draft of the paper published as Shaw et al, 2007, The Use of Exhaled Nitric Oxide to Guide Asthma Management: A Randomised Controlled Trial, American Journal of Respiratory and Critical Care Medicine, 176, pp. 231-237. Official Journal of the American Thoracic Society, ©American Thoracic Society. The final published version is available at http://ajrccm.atsjournals.org/, Doi: 10.1164/rccm.200610-1427OC.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
Revision 1 blue 200610 1427OC.pdf152.78 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.